An observational study in Venous Embolism of Lower Extremities (Diagnosis), Arterial Embolism and Thrombosis and Acute DVT of Lower Extremity, sponsored by Medtronic Endovascular. Completed at 6 sites in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Medtronic Endovascular (part of Medtronic) · Observational
The purpose of Case-Specific Health Care Professional (HCP) Clinical Survey of Liberant™ Thrombectomy System, also known as the Liberant Clinical Assessment, is to collect first-in-human clinical data to confirm the safety and performance of the Medtronic Liberant™ thrombectomy system when used for the removal of fresh, soft emboli or thrombi from the vessels of the peripheral arterial and venous systems
The Liberant Clinical Assessment is a multicenter, prospective per patient HCP recollection survey. Participating HCPs will document their individual case experience following routine utilization of Liberant in accordance with the approved device labeling. Individual use cases will be entered within 72 hours of device usage to identify periprocedural incidents of risk and evaluate device performance. At least 50 use cases will be collected and aggregated from at least 10 participating HCPs. This data collection is for a single point in time, with no patient follow-up. Individual HCP responses for each case will be aggregated by a third party vendor.
785 studies on the registry are indexed under Venous Thrombosis; 110 are open to participants now.
This study's enrollment of 51 is below the median of 301 across 274 observational studies indexed under Venous Thrombosis.
Browse Venous Thrombosis studies →Medtronic Endovascular is the lead sponsor of 51 studies on the registry; 2 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
Compared within Venous Thrombosis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Disease. The counts are of registry records indexed under each term, refreshed daily. How we classify →
The Liberant thrombectomy system is intended for use in adult patients with occluded peripheral arterial and venous vessels.
Patient case selection to be included in the clinical assessment will be specific to Liberant and will be made according to the following criteria:
The Liberant thrombectomy system is indicated for the removal of fresh, soft emboli or thrombi from the vessels of the peripheral arterial and venous systems
Rate of Device related Serious Adverse Event at Index procedure
An Adverse Event that converted to Serious Adverse Event, involving the function of the subject device, or the presence of the device in the body, including events that are directly attributable to the Liberant Thrombectomy System
Time frame: Index Procedure
Rate of technical success at Index procedure
Technical success: Successful introduction, delivery, aspiration of fresh, soft emboli or thrombi, and retrieval of the Liberant per the Instructions for Use (IFU) during the index procedure
Time frame: Index procedure
Rate of Procedural Success at Index procedure
Procedure success: Successful removal of fresh, soft emboli or thrombi and restoration of adequate blood flow, inclusive of all endovascular therapies during the index procedure
Time frame: Index procedure
Plan to share: No — No patients will be engaged, and no medical records will be accessed or used. Individual HCP responses for each case will be aggregated into a final report.
No publications or documents are linked to this record.
Ran from Feb 2026 to primary completion in Oct 2026, 8 months.
Of 127 observational studies under Venous Thrombosis, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 82. This study's 8 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.